Psychopharm in 2019: Your Ultimate Guide скачать в хорошем качестве

Psychopharm in 2019: Your Ultimate Guide

In this podcast episode, we review the major FDA approvals in psychopharmacology for 2019. We explore brexanolone, bremelanotide, asenapine skin patch, esketamine, and cariprazine. 00:00 Welcome 01:52 Brexanolone (Zulresso) 04:27 Bremelanotide (Vyleesi) 08:31 Transdermal Asenapine (Secuado) 08:58 Esketamine (Spravato) 9:44 Cariprazine (Vraylar) 10:45 Lumateperone (Caplyta) 11:41 Key Points 12:34 Credits & References Key Points: Brexanolone is approved for postpartum depression, given in IV infusion and acts on the as a GABA-A receptor modulator. Bremelanotide is for hypoactive sexual desire disorder in premenopausal women. Given in a subcutaneous injection and acts as an agonist on melanocortin receptors. Transdermal asenapine is the first skin patch antipsychotic. It is approved for adult schizophrenia. Esketamine is administered intranasally for treatment-resistant depression in adults who are taking another antidepressant. It is an NMDA receptor antagonist. Cariprazine is now FDA approved for bipolar I depression. Lumateperone has just been approved for adult schizophrenia as the first-of-class antipsychotic. Are you a mental health clinician and want to brush up on psychopharm prescribing? We have what you need! Find the rest of Psychopharmacology Institute podcasts here: Itunes: https://itunes.apple.com/us/podcast/p... Spotify: https://open.spotify.com/show/7lzv8HK... Stitcher: https://www.stitcher.com/s?fid=215561... Google Podcasts: https://www.google.com/podcasts?feed=... RSS: http://psychopharmacology.libsyn.com/... Website: https://psychopharmacologyinstitute.c... Email us at: podcast@psychopharmacologyinstitute.com